Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences

Read full text Summarise with VIRAT
Authors: Matthew Quaife, Cecilia Jimenez‐Moreno, Blanca Gros Otero, Aisha Mariam Asra, Niodita Gupta‐Werner, Katharine S. Gries, M Leisten, Kathryn Matt, Robin L. Carson, Robyn M. Dennis, Jianming He, Bennett S. Levitan
+1 more Sacheeta Bathija
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

AIMS: To understand disease perceptions and treatment preferences of patients with high-risk smoldering multiple myeloma (HR-SMM) or multiple myeloma (MM) that recently progressed from HR-SMM, and to estimate the minimum progression-free survival (min-PFS) required to accept the treatment burden. METHODS: This mixed-methods study interviewed 50 patients (HR-SMM and MM 1:1) from the USA, France, Italy, and Spain. Qualitative semi-structured interviews explored symptoms, quality of life, and awareness and expectations of SMM treatments. A quantitative thresholding exercise elicited the min-PFS for patients to accept a hypothetical treatment. Results were reported for HR-SMM and MM. RESULTS: = 31/44) accepted physician recommendations that treatment was not needed, burdensome, or not available. Twenty-three patients (61%) were willing to start treatment while having HR-SMM. Patients expected treatments to delay disease progression (30%) or increase life expectancy (24%), whereas 22% expected to be "cured" if treated. The min-PFS for the given treatment was 60 months; 61 and 59 months for HR-SMM and MM, respectively. CONCLUSIONS: Considerable psychological, physical, and functional burdens were imposed on HR-SMM patients by potential disease progression. Most patients were willing to receive treatment to delay progression and reduce symptomatic burden.

Publication details

Journal / source
Future Oncology
Publisher
Future Medicine
Volume
22
Issue
19
Pages
2299-2311
Document type
Article